cyclophosphamide + dendritic cell vaccine + docetaxel + epirubicin

This is a multimodal cancer treatment approach combining immunotherapy with chemotherapy. The combination includes: 1. **Cyclophosphamide**: An alkylating agent that at low doses can enhance immune responses by selectively depleting regulatory T cells (Tregs) and promoting effector T cell differentiation. 2. **Dendritic cell vaccine**: A personalized immunotherapy where dendritic cells are loaded with tumor antigens to stimulate anti-tumor immune responses. 3. **Docetaxel**: A taxane chemotherapy agent that disrupts microtubule function. 4. **Epirubicin**: An anthracycline chemotherapy agent that intercalates DNA. The cyclophosphamide component is typically administered at low doses before dendritic cell vaccination to reduce immunosuppressive Tregs and enhance vaccine efficacy. This combination approach aims to overcome tumor-induced immune suppression while directly targeting cancer cells through multiple mechanisms.